within Pharmacolibrary.Drugs.ATC.N;

model N07XX17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 9.833333333333334e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Arimoclomol is an investigational small molecule that amplifies the production of heat shock proteins (HSPs). It is being developed for the treatment of orphan neurodegenerative diseases such as Niemann-Pick disease type C, amyotrophic lateral sclerosis (ALS), and inclusion body myositis. As of 2024, arimoclomol is not approved by major regulatory bodies such as the FDA or EMA, but has been evaluated in several clinical trials.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained in adult healthy volunteers; the drug was administered orally in single and multiple ascending dose studies.</p><h4>References</h4><ol><li><p>Cudkowicz, ME, et al., &amp; Barber, JR (2008). Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. <i>Muscle &amp; nerve</i> 38(1) 837–844. DOI:<a href=&quot;https://doi.org/10.1002/mus.21059&quot;>10.1002/mus.21059</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18551622/&quot;>https://pubmed.ncbi.nlm.nih.gov/18551622</a></p></li><li><p>Phukan, J (2010). Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. <i>IDrugs : the investigational drugs journal</i> 13(7) 482–496. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20582873/&quot;>https://pubmed.ncbi.nlm.nih.gov/20582873</a></p></li><li><p>Kirkegaard, T, et al., &amp; Platt, FM (2016). Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. <i>Science translational medicine</i> 8(355) 355ra118–None. DOI:<a href=&quot;https://doi.org/10.1126/scitranslmed.aad9823&quot;>10.1126/scitranslmed.aad9823</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27605553/&quot;>https://pubmed.ncbi.nlm.nih.gov/27605553</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX17;
